Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Friday, December 30, 2011

Biotech /Pharma Stock Trading Alert: Antares (NYSE Amex: AIS) Moves Up 30% From December 15th Lows

December 15th; “Antares Sell-Off is a Holiday Gift”- Josh Levine  


Point Roberts, WA- December 30 , 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert and updated commentary from Josh Levine of the Levine MicroCap Newsletter, for Antares Pharma, Inc. (NYSE Amex: AIS).

The stock is trading at $2.20, up strongly from its sell off and low of $1.51 on December 15th, following news from partner BioSante Pharmaceuticals.

Following up his comments about AIS on December 15, Josh Levine said today: “Antares has surged 30% in two weeks and is again trading above its 200-day moving average. The market quickly and correctly recognized that the LibiGel event does nothing to tarnish the company’s outlook, which has never been stronger.”



December 15th- “Antares Sell-Off is a Holiday Gift”- Josh Levine -

“After the market close yesterday, Antares Pharma (AIS) partner Biosante reported results from two Phase III efficacy trials for Libigel, which is used to treat hypoactive sexual desire disorder in post-menopausal women. Here’s the bottom line: While Libigel was extremely effective and reinforced previous studies, the placebo group fared nearly as well. The failure appears to have been due to a surprisingly high placebo effect. The impact on Biosante is devastating, but it’s only a minor bump in the road for Antares. Today’s 30%-plus drop in AIS shares is an overreaction and the stock will rebound fully in time.”

He also noted, “Libigel, if successful, would have only begun contributing revenues to Antares in 2015.”

About Josh Levine and Levine's MicroCap Investor   www.levinesmicrocapinvestor.com
Josh Levine has 25 years of senior-level experience in analyzing technology trends and investing in top-performing micro- and small-cap stocks.

About Antares Pharma, Inc. (NYSE Amex: AIS)
Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include VIBEX™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is Anturol® gel, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for the U.S. and Canada. Antares’ partnership with BioSante includes LibiGel® transdermal testosterone gel in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin® estradiol gel indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has two facilities in the U.S. The Parenteral Products Division located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma Division are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.

Get biotech news and stock alerts  
http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure. BPAX compensates investorideas .com for news release dissemination and content creation. BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com



Thursday, December 15, 2011

Biotech/ Pharma Stock Trading Alert: Antares (NYSE Amex: AIS) Trades Down on BioSante News

Point Roberts, WA - December 15, 2011 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Antares Pharma, Inc. (NYSE Amex: AIS). The stock is trading down at $1.63, down 0.78 (32.37%) 12:28PM EST with a low of $1.51, following news from partner BioSante Pharmaceuticals.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced on the close yesterday that its top-line results from its two pivotal Phase III LibiGel (testosterone gel) efficacy trials. Initial analysis of the data from these trials shows that the trials did not meet the co-primary or secondary endpoints. Although there were no statistical differences in the endpoints, all results were in the appropriate directions. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in postmenopausal women, for which there is no FDA-approved product. BioSante is trading down at $0.4801, down 1.6399 (77.35%) 12:28PM EST.
Antares' partnership with BioSante includes LibiGel® transdermal testosterone gel in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD).
"Antares Sell-Off is a Holiday Gift"- Josh Levine
"After the market close yesterday, Antares Pharma (AIS) partner Biosante reported results from two Phase III efficacy trials for Libigel, which is used to treat hypoactive sexual desire disorder in post-menopausal women. Here's the bottom line: While Libigel was extremely effective and reinforced previous studies, the placebo group fared nearly as well. The failure appears to have been due to a surprisingly high placebo effect. The impact on Biosante is devastating, but it's only a minor bump in the road for Antares. Today's 30%-plus drop in AIS shares is an overreaction and the stock will rebound fully in time."
He also noted, "Libigel, if successful, would have only begun contributing revenues to Antares in 2015."
About Josh Levine and Levine's MicroCap Investorwww.levinesmicrocapinvestor.com
Josh Levine has 25 years of senior-level experience in analyzing technology trends and investing in top-performing micro- and small-cap stocks.
About Antares Pharma, Inc. (NYSE Amex: AIS)
Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include VIBEX™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is Anturol® gel, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for the U.S. and Canada. Antares' partnership with BioSante includes LibiGel® transdermal testosterone gel in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin® estradiol gel indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has two facilities in the U.S. The Parenteral Products Division located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company's reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company's corporate offices and Pharma Division are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company's transdermal systems and drug/device combination products.
Investorideas.com Newswire Get biotech news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure. BPAX compensates investorideas .com for news release dissemination and content creation. BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Wednesday's Biotech/ Pharma Stocks Trading; (NASDAQ:AMRI), (NASDAQ:VPHM), (NASDAQ:ZLCS), (NASDAQ:ILMN)

Point Roberts, WA - December 15, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Wednesday, December 14, 2011.
Albany Molecular Research, Inc. (NASDAQ:AMRI) shares gained 0.43 (18.53%) to close at $2.75, rebounding from its recent lows and the stock has surged around 35% over the past 3 weeks.
ViroPharma Incorporated (NASDAQ:VPHM) ended higher by 4.21 (17.85%) to close at $27.80 on very unusual volume and made a new 52-week high of $28.34 after the company reported that U.S. health regulators approved a new and expanded label for its antibiotic Vancocin, which the biotechnology company expects will grant the drug three years of protection from generic versions.
Zalicus, Inc. (NASDAQ:ZLCS) rose 0.10 (9.26%) and closed at $1.18, extending its weekly gains to over 24% on increased volume. Zalicus Inc. (Zalicus), formerly CombinatoRx, is a biopharmaceutical company developing drug candidates with a focus on the treatment of pain and inflammation.
Illumina, Inc. (NASDAQ:ILMN) moved higher by 1.25 (4.82%) to end at $27.21, rebounding from its 52-week low made recently. The stock has a 52-week range of $25.57-$79.40. Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
Cornerstone Therapeutics, Inc. (NASDAQ:CRTX) climbed 0.52 (10.24%) to finish at $5.60 on high volume. Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . Disclosure: BioSante (BPAX) is a paid online advertising company on Investorideas.com (six thousand five hundred for three months)
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Wednesday, December 14, 2011

OTC Biotech Stock News; Aethlon (OTCBB: AEMD) Reports HIV Breakthrough

San Diego, December 14, 2011 - (Investorideas.com Biotech/PharmaNewswire) HIV Medical Technology News Update - Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic filtration devices to address infectious disease and cancer, reports that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS).
Aethlon Medical's Hemopurifier® is a first-in-class therapeutic device that selectively targets the clearance of viruses, immunosuppressive proteins, and disease enhancing exosomes from the entire the entire circulatory system.
Nef or "Negative Factor" protein is a highly abundant HIV accessory protein that plays an essential role in AIDS progression, yet has eluded HIV drug discovery efforts. Nef protein is secreted from infected cells in small membrane-bound packages called "exosomes." These exosomes fuse with non-infected cells and cause a variety of effects, including programmed cell death of CD4+ immune cells, the hallmark of AIDS. The Hemopurifier® provides a strategy to address Nef exosomes, which are present in the blood of HIV infected individuals. In an ex vivo validation study conducted by researchers at Morehouse School of Medicine, a small-scale Hemopurifier® reduced the presence of Nef exosomes in cell-culture fluids by greater than 85% in less than 24 hours. The outcome represents the first demonstration that a medical device can selectively target Nef exosomes.
"It is becoming increasingly clear that many viruses, including HIV, exploit the mechanisms of exosome production for their secretion and pathogenesis," stated Michael Powell, Ph.D., Associate Professor and Director of Proteomics, Microbiology, Biochemistry, and Immunology at Morehouse School of Medicine. "Therefore, therapies that target circulating exosomes hold great promise to advance antiviral strategies."
In addition to Nef exosomes, the Hemopurifier® is the subject of multi-cancer studies against tumor-secreted exosomes that facilitate the ability of cancerous tumors to evade the immune response. Tumor-secreted exosomes are implicated in the survival, growth, and metastasis of cancer. Additionally, the Hemopurifier® is being evaluated in human studies as an adjunct therapy to improve outcomes of HCV patients receiving interferon therapy.
"First and foremost, our clinical focus is to demonstrate that our Hemopurifier® improves the benefit of Hepatitis-C virus (HCV) therapies, stated Jim Joyce, CEO and founder of Aethlon Medical. �However, when considering our previous HIV treatment experience, the emerging insight that we can address Nef exosomes provides a further basis for us to pursue clinical opportunities to treat HIV-infected individuals," stated Jim Joyce, CEO and founder of Aethlon Medical.
In a previous proof-of-principle study, an HIV-infected dialysis patient diagnosed with AIDS received Hemopurifier® therapy during his normal dialysis treatment, resulting in the administration of three weekly Hemopurifier® treatments over the period of one month. The study was conducted in the absence of any antiviral drug administration. In addition to demonstrating treatment safety in an immune-compromised AIDS patient, HIV viral load of the patient was reduced from 102,759 iu/ml at the beginning of treatment one to a final value of 7,978 iu/ml at the end of treatment twelve, representing a 92% reduction. Viral load remained 56% below initial testing values when measured 14-days after last Hemopurifier(r) therapy. Additionally, CD4 t-cell to lymphocyte ratios increased from 13.5% to 18.05% during the study. A ratio below 15% represents a clinical definition of AIDS. The study was conducted at the Sigma New Life Hospital in India.
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture tumor-secreted exosomes and to captureNef protein exosomes and the impact that capture may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contact:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com
Learn more about OTCBB: AEMD
http://www.investorideas.com/CO/AEMD/
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes. AEMD has paid Investorideas.com four thousand for the email distribution and online distribution of this release through its network including Stock Profiler and Investorideas.com growing network of online financial media.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Pharma News: Unity Management Group (OTC: UYMG) Reports Initial Sale of PZ UNO Tablet press to Major Pharmaceutical Company for $500,000.

East Hanover, N.J. - December 14, 2011 (Investorideas.com Newswire) - Unity Management Group, Inc. (OTCBB: UYMG) and its subsidiary, Metropolitan Computing Corporation (MCC) are pleased to announce that it has sold its initial PZ Uno Tablet press to a major pharmaceutical company for $500,000. Due to confidentiality agreements the company is not able to disclose the name of the purchaser. The company did specify that the PZ Uno tablet press would be used for a research and development project for clinical trials for a revolutionary new drug.
Unity Management Group Inc. is pleased with the first sale, and reference point for the new press, and projects sales for the PZ UNO Tablet Press for 2012 to be substantial, said Michael Oliver Director, and Vice president, and he also stated that Unity Management is on pace to finalize their 2011 goals in new sales and finalizing pending orders.
About Unity Management Group, Inc.
Unity Management Group, a health resource company, will continue to provide innovative physician practice management services that offer high value and significant return on investment for physicians practices and hospitals through its three subsidiary companies: United Healthcare Solutions Inc., Unity Technologies Inc., and United Business Services Inc.
The first subsidiary, Unity Business Services, is a full service management company offering solutions in practice management, billing, staffing, contracting, licensing, credentialing, and accounting. Unity Business Services also offers assistance in HIPAA compliance, marketing, and unique solutions for practice start-ups and new practices.
Unity Technologies Inc. is a complete software solutions company offering billing, electronic medical records, and electronic health records for physicians' offices and hospitals.
United Healthcare Solutions, a national company based in Nevada , is a healthcare company will be providing medical, vision and dental plans, as well as PPO and HMO networks.
For more information please go to our website which can be found at www.unitymanagementgroup.com www.mcc-online.com
Text stock to: 313131 for our weekly newsletter
Certain information discussed in this press release may constitute forward-looking statements within the Private Securities Litigation Reform Act of 1995 and the federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions at the time made, it can give no assurance that its expectations will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to unpredictable and unanticipated risks, trends and uncertainties such as the Company's inability to accurately forecast its operating results; the Company's potential inability to achieve profitability or generate positive cash flow; the availability of financing; and other risks associated with the Company's business. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequen! t events.
Investor Relations Contact
Michael Oliver
SOURCE: Unity Management Group, Inc.

Tuesday, December 13, 2011

Biotech Trading News Alert: Aethlon Medical (OTCBB: AEMD) Trades Up over 9% on News of HIV-AIDS Research Discovery

Point Roberts, WA - December 13, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for Aethlon Medical, Inc. (OTCBB:AEMD) following news of its HIV-AIDS research discovery. The stock is trading up over 9% on 160,000 shares in morning trading.
Investorideas.com Newswire Aethlon Medical, Inc. (OTCBB:AEMD) the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS). The Aethlon Hemopurifier® is a first-in-class therapeutic device that selectively targets the clearance of viruses, immunosuppressive proteins, and disease enhancing exosomes from the entire the entire circulatory system.
Full news: http://finance.yahoo.com/news/Aethlon-Medical-Announces-HIV-prnews-3930211403.html?x=0
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Contact:
James A. Joyce
Chairman and CEO
858.459.7800 x301
learn more about OTCBB: AEMD
http://www.investorideas.com/CO/AEMD/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get free investor news and stock alerts
Sign Up:  http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes. AEMD has paid Investorideas.com four thousand for the email distribution and online distribution of this release through its network including Stock Profiler and Investorideas.com growing network of online financial media.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Biotech Stock Investor News Alert; Aethlon Medical (OTCBB: AEMD) Announces HIV-AIDS Research Discovery

San Diego, December 13, 2011 - (Investorideas.com Newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS). The Aethlon Hemopurifier® is a first-in-class therapeutic device that selectively targets the clearance of viruses, immunosuppressive proteins, and disease enhancing exosomes from the entire the entire circulatory system.
Nef or "Negative Factor" protein is a highly abundant HIV accessory protein that plays an essential role in AIDS progression, yet has eluded HIV drug discovery efforts. Nef protein is secreted from infected cells in small membrane-bound packages called "exosomes." These exosomes fuse with non-infected cells and cause a variety of effects, including programmed cell death of CD4+ immune cells, the hallmark of AIDS. The Hemopurifier ® provides a strategy to address Nef exosomes, which are present in the blood of HIV infected individuals. In an ex vivo validation study conducted by researchers at Morehouse School of Medicine, a small-scale Hemopurifier® reduced the presence of Nef exosomes in cell-culture fluids by greater than 85% in less than 24 hours. The outcome represents the first demonstration that a medical device can selectively target Nef exosomes.
"It is becoming increasingly clear that many viruses, including HIV, exploit the mechanisms of exosome production for their secretion and pathogenesis," stated Michael Powell, Ph.D., Associate Professor and Director of Proteomics, Microbiology, Biochemistry, and Immunology at Morehouse School of Medicine. "Therefore, therapies that target circulating exosomes hold great promise to advance antiviral strategies."
In addition to Nef exosomes, the Hemopurifier® is the subject of multi-cancer studies against tumor-secreted exosomes that facilitate the ability of cancerous tumors to evade the immune response. Tumor-secreted exosomes are implicated in the survival, growth, and metastasis of cancer. Additionally, the Hemopurifier® is being evaluated in human studies as an adjunct therapy to improve outcomes of HCV patients receiving interferon therapy.
" First and foremost, our clinical focus is to demonstrate that our Hemopurifier® improves the benefit of Hepatitis-C virus (HCV) therapies, stated Jim Joyce, CEO and founder of Aethlon Medical. "However, when considering our previous HIV treatment experience, the emerging insight that we can address Nef exosomes provides a further basis for us to pursue clinical opportunities to treat HIV-infected individuals," stated Jim Joyce, CEO and founder of Aethlon Medical.
In a previous proof-of-principle study, an HIV-infected dialysis patient diagnosed with AIDS received Hemopurifier® therapy during his normal dialysis treatment, resulting in the administration of three weekly Hemopurifier® treatments over the period of one month. The study was conducted in the absence of any antiviral drug administration. In addition to demonstrating treatment safety in an immune-compromised AIDS patient, HIV viral load of the patient was reduced from 102,759 iu/ml at the beginning of treatment one to a final value of 7,978 iu/ml at the end of treatment twelve, representing a 92% reduction. Viral load remained 56% below initial testing values when measured 14-days after last Hemopurifier(r) therapy. Additionally, CD4 t-cell to lymphocyte ratios increased from 13.5% to 18.05% during the study. A ratio below 15% represents a clinical definition of AIDS. The study was conducted at the Sigma New Life Hospital in India.
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture tumor-secreted exosomes and to captureNef protein exosomes and the impact that capture may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contact:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com
Learn more about OTCBB: AEMD
http://www.investorideas.com/CO/AEMD/
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes. AEMD has paid Investorideas.com four thousand for the email distribution and online distribution of this release through its network including Stock Profiler and Investorideas.com growing network of online financial media.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Monday, December 12, 2011

Biotech/ Pharma Stocks To Watch; Friday's Gainers: (NASDAQ:PARDD), (NASDAQ:LXRX), (NASDAQ:ACHN), (NASDAQ:TNGN)

Point Roberts, WA - December 12, 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Friday, December 09, 2011.
Poniard Pharmaceuticals, Inc. (NASDAQ:PARDD) was the biggest gainer within the sector and soared 13.91% to close at $3.85, with most of gains coming in the final hour of the trading session without any major news. The stock was probably bounced back after falling over 30% during the past week.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ended higher by 13.39% to end at $1.27 on very unusual volume 919K shares, compared to its average volume of 566K shares. The stock bounced back from its recent fall and closed the week with gains of over 5%.
Tengion, Inc. (NASDAQ:TNGN) added 11.63% and closed at $0.475, extending its weekly gains to over 18% on increased volume. Last week, the company announced the appointment of John L. Miclot as its President and Chief Executive Officer (CEO)
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) moved up by 10.10% to close at $7.52 on high volume and recovered all its losses earlier during the week. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) soared 9.57% to finish at $8.13, bouncing back from its recent fall. Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . Disclosure:
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Friday, December 9, 2011

Thursday's Biotech Stocks to Watch; (NASDAQ:AFFY), (NASDAQ:DARA), (NASDAQ:SGEN), (NASDAQ:CTIC)

News about Affymax, Inc. (NASDAQ:AFFY)
Point Roberts, WA - December 9, 2011 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Thursday December 08, 2011.
Affymax, Inc. (NASDAQ:AFFY) shares gained 2.12 (36.22%) to end at $7.98 after A Food and Drug Administration panel voted in favor of the biotech drugmaker's experimental treatment for patients with anemia.
DARA Biosciences Inc. (NASDAQ:DARA) ended higher by 0.11 (9.65%) to close at $1.25 on very unusual volume after the company announced that Richard A. Franco, Sr. will retire as Chairman, President and Chief Executive Officer and as a director effective as of December 16, 2011.
Seattle Genetics, Inc. (NASDAQ:SGEN) rose 0.88 (5.15%) and closed at $17.98, extending its weekly gains to over 19% on increased volume. The company announced today that management will present at the following upcoming investor conference. Oppenheimer 22nd Annual Healthcare Conference Wednesday, December 14, 2011 at 2:10 p.m. Eastern Time in New York, NY
Synageva BioPharma Corp. (NASDAQ:GEVA) moved higher by 0.77 (4.10%) to end at $19.57 and made a new 52-week high of $19.74, extending its weekly gains to over 15% on heavy volume. The stock has a 52-week range of $10.04-$19.74.
Cell Therapeutics, Inc. (NASDAQ:CTIC) climbed 0.03 (2.22%) to close at $1.38 on high volume. Today morning, the company announced that it has entered into an agreement to sell, subject to customary closing conditions, $20 million of shares of its Series 14 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to two institutional investors.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Thursday, December 8, 2011

Biotech/Pharma Stock Trading Alert: Affymax (NasdaqGS: AFFY) Trades Up 37% on FDA Advisory Committee Vote

POINT ROBERTS, December 8, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues a trading alert for Biotech/Pharma stock, Affymax, Inc. (NasdaqGS: AFFY) trading at $8.06, up 2.20 (37.50%) 2:09PM EST. The stock has a high of $8.45 in today’s trading session.

Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease (CKD).


About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Research and trade biotech and pharma stocks with the global stock directory :
http://www.investorideas.com/BIS/Stock_List.asp

Visit our biotech stocks research page:
http://www.investorideas.com/BIS/

Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more.  Join: http://www.investorideas.com/membership/

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp

800-665-0411 - Source – www.Investorideas.com

Wednesday, December 7, 2011

Tuesday's Biotech/ Pharma Stocks to Watch; (NASDAQ:PPHM), (NASDAQ:BPAX), (NASDAQ:ONTY), (NASDAQ:CTIC)

Point Roberts, WA - December 7, 2011 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Tuesday, December 06, 2011.
Peregrine Pharmaceuticals (NASDAQ:PPHM) was the biggest percentage gainer and soared 0.21 (21.02%) to $1.21 after news that Peregrine Pharmaceuticals Inc's experimental lung cancer therapy reduced more tumors than standard treatment in a mid-stage study.
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) ended flat at $2.56 on high volume of 1.52 million shares. The stock has gained above 15% over the past week. The stock was featured at The Street.com in a video - The Next Big Things In Biotech: Biosante. Several analysts and newsletters are watching Biosante stock as catalysts that can move it higher come into play in December. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).
Oncothyreon Inc.(NASDAQ:ONTY) traded higher by 1.02 (14.29%) and closed at $8.16 after gaining over about 4% in the previous trading session on news that Bob Kirkman, the CEO of the company took an unexplained medical leave from the company back in September. The company said at the time he'd return for the fourth quarter of 2011; he's back on the job as CEO.
Cell Therapeutics, Inc.(NASDAQ:CTIC) moved higher by 13.04% to $1.30 following news the company announced that the U.S. Food and Drug Administration's Division of Oncology Products 1 has notified CTI that CTI's October 2011 resubmitted New Drug Application ("NDA") is considered complete.
Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) climbed 0.83 (7.79%) to $083 on high volume. In the pre-market session, the stock added another 12% after the company provided update on clinical progress with sapacitabine in solid tumors including activity in BRCA mutation-positive patients.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join:   http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . Disclosure: BioSante (BPAX) is a paid online advertising company on Investorideas.com (six thousand five hundred for three months)
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Tuesday, December 6, 2011

Biotech and Pharma Stock Alert; Aethlon Medical (OTC: AEMD) Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes

SAN DIEGO - December 6, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier® to capture tumor-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California . The study will enroll up to 25 patients with metastatic cancer, including those with non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma. Testing of blood samples provided by three enrolled sarcoma patients has already been initiated. The study goal is to establish the first validation that a medical device, the Aethlon Hemopurifier®, can effectively capture tumor-secreted exosomes from the blood of cancer patients. Successful study outcomes would provide a basis for follow-on human treatment studies in cancer patients.
Tumor-secreted exosomes, which are not addressed by drug therapy, assist cancerous tumors in evading the immune response and are implicated in the survival, growth, and metastasis of cancer. The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens, including HIV and Hepatitis C virus (HCV). The device has also demonstrated the ability to capture tumor-secreted exosomes from cell culture and human ascites fluids. At present, the Hemopurifier® is being evaluated in human studies as an adjunct therapy to improve outcomes of HCV patients receiving interferon therapy.
The Sarcoma Oncology Center is a highly sought after research center for the clinical testing of new therapeutic candidates against sarcomas and other forms of cancer. Dr. Sant Chawla , the lead investigator of the study is a recognized authority in the sarcoma oncology field.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT� System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT� product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome� to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT� system including the ability to introduce a targeted breast cancer therapy known as HER2osome�, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture tumor-secreted exosomes and the impact it may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)